215 related articles for article (PubMed ID: 9652416)
1. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
Ashley RL; Crisostomo FM; Doss M; Sekulovich RE; Burke RL; Shaughnessy M; Corey L; Polissar NL; Langenberg AG
J Infect Dis; 1998 Jul; 178(1):1-7. PubMed ID: 9652416
[TBL] [Abstract][Full Text] [Related]
2. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
[TBL] [Abstract][Full Text] [Related]
3. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs.
Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI
J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506
[TBL] [Abstract][Full Text] [Related]
4. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
Awasthi S; Belshe RB; Friedman HM
J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
[TBL] [Abstract][Full Text] [Related]
5. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
Langenberg AG; Burke RL; Adair SF; Sekulovich R; Tigges M; Dekker CL; Corey L
Ann Intern Med; 1995 Jun; 122(12):889-98. PubMed ID: 7755223
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L
J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031
[TBL] [Abstract][Full Text] [Related]
7. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
Awasthi S; Huang J; Shaw C; Friedman HM
J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
[TBL] [Abstract][Full Text] [Related]
8. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
[TBL] [Abstract][Full Text] [Related]
9. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
10. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A
Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
[TBL] [Abstract][Full Text] [Related]
12. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
Awasthi S; Balliet JW; Flynn JA; Lubinski JM; Shaw CE; DiStefano DJ; Cai M; Brown M; Smith JF; Kowalski R; Swoyer R; Galli J; Copeland V; Rios S; Davidson RC; Salnikova M; Kingsley S; Bryan J; Casimiro DR; Friedman HM
J Virol; 2014 Feb; 88(4):2000-10. PubMed ID: 24284325
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
14. Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge.
Heineman TC; Pesnicak L; Ali MA; Krogmann T; Krudwig N; Cohen JI
Vaccine; 2004 Jun; 22(20):2558-65. PubMed ID: 15193381
[TBL] [Abstract][Full Text] [Related]
15. Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.
Mbopi-Kéou FX; Bélec L; Dalessio J; Legoff J; Grésenguet G; Mayaud P; Brown DW; Morrow RA
Clin Diagn Lab Immunol; 2003 May; 10(3):388-93. PubMed ID: 12738636
[TBL] [Abstract][Full Text] [Related]
16. Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.
Wang K; Dropulic L; Bozekowski J; Pietz HL; Jegaskanda S; Dowdell K; Vogel JS; Garabedian D; Oestreich M; Nguyen H; Ali MA; Lumbard K; Hunsberger S; Reifert J; Haynes WA; Sawyer JR; Shon JC; Daugherty PS; Cohen JI
J Infect Dis; 2021 Nov; 224(9):1509-1519. PubMed ID: 33718970
[TBL] [Abstract][Full Text] [Related]
17. Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections.
Ashley RL; Corey L; Dalessio J; Wilson P; Remington M; Barnum G; Trethewey P
J Infect Dis; 1994 Jul; 170(1):20-6. PubMed ID: 8014499
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
20. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.
Bernstein DI; Earwood JD; Bravo FJ; Cohen GH; Eisenberg RJ; Clark JR; Fairman J; Cardin RD
Vaccine; 2011 Mar; 29(11):2071-8. PubMed ID: 21238569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
